Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 58

Cited In for PubMed (Select 20801498)


Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics.

Beitelshees AL, Voora D, Lewis JP.

Pharmgenomics Pers Med. 2015 Feb 9;8:43-61. doi: 10.2147/PGPM.S52900. eCollection 2015. Review.


Routine screening for CYP2C19 polymorphisms for patients being treated with clopidogrel is not recommended.

Bhopalwala AM, Hong RA, Khan ZR, Valentin MR, Badawi RA.

Hawaii J Med Public Health. 2015 Jan;74(1):16-20.


Insurance coverage policies for personalized medicine.

Hresko A, Haga SB.

J Pers Med. 2012 Oct 30;2(4):201-16. doi: 10.3390/jpm2040201.


Southern Saskatchewan Ticagrelor Registry experience.

Dehghani P, Chopra V, Bell A, Kelly S, Zulyniak L, Booker J, Zimmermann R, Semchuk W, Cheema AN, Lavoie AJ.

Patient Prefer Adherence. 2014 Oct 16;8:1427-35. doi: 10.2147/PPA.S68423. eCollection 2014.


Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.

Dobesh PP, Oestreich JH.

Pharmacotherapy. 2014 Oct;34(10):1077-90. doi: 10.1002/phar.1477. Epub 2014 Aug 28.


Pharmacogenomic substudies of randomized controlled trials: consideration of safety outcomes.

Sorich MJ, Rowland A, Wiese MD.

Ther Adv Drug Saf. 2014 Apr;5(2):62-6. doi: 10.1177/2042098613520030. No abstract available.


Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention.

Siller-Matula JM, Lang IM, Neunteufl T, Kozinski M, Maurer G, Linkowska K, Grzybowski T, Kubica J, Jilma B.

PLoS One. 2014 Jul 22;9(7):e102701. doi: 10.1371/journal.pone.0102701. eCollection 2014.


Cardiovascular drugs and the genetic response.

Dandona S.

Methodist Debakey Cardiovasc J. 2014 Jan-Mar;10(1):13-7. Review.


Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project).

Vrijens B, Claeys MJ, Legrand V, Vandendriessche E, Van de Werf F.

Br J Clin Pharmacol. 2014 May;77(5):746-55.


Development of a multiplex and cost-effective genotype test toward more personalized medicine for the antiplatelet drug clopidogrel.

Jeong HE, Lee SJ, Cha EY, Kim EY, Kim HS, Song YH, Shin JG.

Int J Mol Sci. 2014 May 5;15(5):7699-710. doi: 10.3390/ijms15057699.


Personalized antiplatelet therapy: state of the art.

Gurbel PA, Jeong YH, Tantry US.

JRSM Cardiovasc Dis. 2012 Sep 24;1(6). pii: cvd.2012.012015. doi: 10.1258/cvd.2012.012015. Review.


Applied pharmacogenomics in cardiovascular medicine.

Weeke P, Roden DM.

Annu Rev Med. 2014;65:81-94. doi: 10.1146/annurev-med-101712-122545. Epub 2013 Oct 2. Review.


Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.

Aradi D, Storey RF, Komócsi A, Trenk D, Gulba D, Kiss RG, Husted S, Bonello L, Sibbing D, Collet JP, Huber K; Working Group on Thrombosis of the European Society of Cardiology.

Eur Heart J. 2014 Jan;35(4):209-15. doi: 10.1093/eurheartj/eht375. Epub 2013 Sep 25. No abstract available.


Oral antiplatelet therapy in acute coronary syndromes: update 2012.

Höchtl T, Sinnaeve PR, Adriaenssens T, Huber K.

Eur Heart J Acute Cardiovasc Care. 2012 Apr;1(1):79-86. doi: 10.1177/2048872612443345.


Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups.

Sorich MJ, Coory M, Pekarsky BA.

PLoS One. 2013 Aug 27;8(8):e72256. doi: 10.1371/journal.pone.0072256. eCollection 2013.


Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical care.

Rothenbacher D, Hoffmann MM, Breitling LP, Rajman I, Koenig W, Brenner H.

BMC Cardiovasc Disord. 2013 Aug 27;13:61. doi: 10.1186/1471-2261-13-61.


Genetics of platelet inhibitor treatment.

Trenk D, Hochholzer W.

Br J Clin Pharmacol. 2014 Apr;77(4):642-53. doi: 10.1111/bcp.12230. Review.


Pharmacogenomic testing and antithrombotic therapy: ready for prime time?

Holmes DR Jr.

Rambam Maimonides Med J. 2013 Jan 30;4(1):e0005. doi: 10.5041/RMMJ.10105. Print 2013 Jan.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk